TARS FY 2022 Earnings — Tarsus Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

TARSTarsus Pharmaceuticals, Inc.

$3B

FY 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$26M-54.7% YoY

Gross Profit

$25M96.3% margin

Operating Income

-$63M-242.9% margin

Net Income

-$62M-240.5% margin

EPS (Diluted)

$-2.52

Cash Flow

Operating Cash Flow

-$49M

Free Cash Flow

-$50M

Stock-Based Comp.

$13M

Balance Sheet

Total Assets

$228M

Total Liabilities

$35M

Stockholders' Equity

$193M

Cash & Equivalents

$72M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$26M	$57M	-54.7%
Gross Profit	$25M	$55M	-54.8%
Operating Income	-$63M	-$12M	-415.9%
Net Income	-$62M	-$14M	-349.1%